Why do people who have never smoked still have lung cancer?
What is the impact of intermittent hypoxia (as seen in sleep apnea) on cardiovascular or metabolic function?
How to reduce or prevent the accumulation and spread of alpha-synuclein (toxic protein) in Parkinson's disease?
How is mutant LRRK2 linked to impaired degradation of waste proteins in brain cells which leads to Parkinson's disease?
What are the mechanisms underlying the cellular and molecular immune dysregulation in SLE?
What are the roles of regulatory noncoding RNAs in SLE pathogenesis?
SLE disease heterogeneity - can SLE patients be stratified by omics analyses?
Is DWI useful for axial spondyloarthritis disease monitoring?
Are there any serum biomarkers that could be used for axial spondyloarthritis monitoring?
What is the relationship between disease progression and intensity of spinal inflammation?
Pluripotent stem cell for disease modeling and treatment of cardiovascular disease.
Tissue engineering for treatment of heart failure.
Small and large animal models for studying the mechanism and treatment of hypertension and heart failure.
Cardiac arrhythmia − mechanisms and treatment of atrial fibrillation and ventricular arrhythmias.
Cardiac pacing − developments in novel pacing technologies for treatment of heart failure and cardiac arrhythmia.
Sudden cardiac death − epidemiology, prevention and treatment.
Precision medicine for coronary heart disease − prediction of coronary artery disease using genetic and multi-omic approaches.
Cardiovascular imaging − development of novel echo and MRI imaging for cardiovascular diseases.
Professor H.F. Tse
Tel: 2255 4694
Cardiovascular risk factors in the community, including hypertension and the metabolic syndrome.
Pharmacogenetics, pharmacogenomics and precision medicine.
Improving drug therapy − clinical trials, meta-analysis of clinical trials, clinical guidelines, assessing utilisation and cost-effectiveness, and drug safety.
Professor B.M.Y. Cheung
Tel: 2255 4347
Endocrinology and metabolism:
Molecular genetics and pathogenesis of atherosclerosis, diabetes and diabetic complications; clinical and basic studies on obesity and adipocyte-derived hormones; adipose tissue browning, immunometabolism; pathogenesis and management of autoimmune thyroid disease; genetics and environmental determinants of osteoporosis.
Professor K.C.B. Tan
Tel: 2255 5255
Gastroenterology and hepatology:
Natural history and risk factors for development of disease complications of chronic hepatitis B infection.
Virology and novel markers for hepatitis B disease.
Novel treatment for chronic hepatitis B infection.
Diagnostic tools and disease characterization of occult hepatitis B infection.
Professor M.F. Yuen
Tel: 2255 4477
Big data research on various GI diseases.
Helicobacter pylori − disease pathogenesis, antibiotics resistance, gastric carcinogenesis.
Stomach and colon cancer − chemoprevention, innovations on screening and surveillance.
Gastrointestinal bleeding − prevention and intervention.
Inflammatory bowel disease: epidemiology and treatment outcome.
Professor W.K. Leung
Tel: 2255 3348
What factors alter disease outcomes in treatment-predominant chronic hepatitis B?
What are the viral and host factors that predict treatment response in novel emerging therapies for chronic hepatitis B?
What are the underlying molecular mechanisms for different phenotypes of non-alcoholic fatty liver disease?
How can we diagnose liver fibrosis non-invasively and apply to clinical use?
What are the disease entities affected by gut microbiota dysbiosis?
Can fecal microbiota transplantation in animal models provide a causative answer to disease outcomes?
Artificial intelligence and deep learning: is machine better than man?
How can artificial intelligence enhance prediction of disease outcomes in different liver diseases?
Chronic hepatitis B: Translational and clinical studies on treatment outcomes and functional cure.
Non-alcoholic fatty liver disease: Animal models and molecular mechanisms.
Liver fibrosis: Novel non-invasive diagnostic techniques and clinical outcomes.
Gut microbiota and fecal microbiota transplantation: Animal models and associations with disease outcomes.
Artificial intelligence: Deep machine learning and its integration in liver disease.
Professor W.W.K. Seto
Tel: 2255 6979
Clinical protocols for treatment of leukaemia and lymphomas; detection of minimal residual disease and molecular mechanisms in haematologic malignancy; clinical protocols for bone marrow transplantation; infective and neoplastic complications of bone marrow transplantation; molecular genetics of haematological malignancies; basic research in pathogenesis of blood cancers; normal and leukaemic haematopoietic stem cell study using NOD/SCID mice; embryonic haematopoiesis and gene regulation studies in zebrafish.
Professor Y.L. Kwong
Tel: 2255 5859
Development of novel diagnostic techniques (including non-invasive prenatal diagnosis and pre-implantation diagnosis) for common genetic diseases, such as thalassemias, haemophilias, Duchenne muscular dystrophy, spinal muscular atrophy and Huntington’s disease; genome-wide scan with microsatellite markers for linkage of new disease genes; development of DNA microarray technology to diagnose and elucidate the molecular pathology of genetic diseases and cancers.
Professor Y.L. Kwong
Tel: 2255 5859
Influenza − rapid diagnostics, vaccination and antiviral treatment (mouse models and clinical trials).
Pneumococcal disease − rapid diagnostics and vaccination (clinical trials).
Respiratory viruses − parainfluenza virus, metapneumovirus, rhinovirus, coronavirus, adenovirus (clinical presentation and antiviral treatment in mouse models and clinical trials).
Multiple drug resistance organisms − infection control and treatment.
Professor I.F.N. Hung
Tel: 2255 4049
Molecular and immunological pathogenic mechanisms of renal inflammation and fibrosis in glomerular and tubulointerstitial diseases, with special focus on lupus nephritis.
Translational studies on peritoneal mesothelial cell biology focusing on inflammation and fibrosis of peritoneal membrane in the context of peritoneal dialysis.
Professor D.T.M. Chan
Tel: 2255 4542
Cellular and molecular mechanisms of proteinuric tubulointerstital disease, diabetic kidney disease and IgA nephropathy.
Stem cell and regenerative medicine in diabetic and non-diabetic models of kidney disease
Integrative medicine in diabetic kidney disease, clinical and basic.
Professor S.C.W. Tang
Tel: 2255 3603
Elucidation of therapeutic targets of pathogenic mechanisms to modify the progressive course of Parkinson's disease.
Professor S.L. Ho
Tel: 2255 2368
Experimental stroke models; neuroimaging of stroke; biomarkers for stroke; high resolution EEG; functional brain mapping.
Professor R.T.F. Cheung
Tel: 2255 4049
Neuroimmunology and Neuroinflammation − clinical, neuroradiological, molecular, immunological and pathological studies of 1) autoimmune and immune-mediated neurological disorders including neuromyelitis optica spectrum disorders (NMOSD), multiple sclerosis (MS), autoimmune encephalitis, autoimmune myasthenia gravis and paraneoplastic neurological disorders; and 2) Alzheimer's disease (AD) aiming at development of novel therapies with anti-inflammatory and neuroprotective properties in NMOSD, MS and AD by cell and animal models as well as human clinical trials.
Intracerebral haemorrhage with specific focus on intracerebral haemorrhage complicating therapy with anticoagulants and antiplatelet agents.
Dr K.H. Chan
Tel: 2255 2368
Stroke and Brain Health:
Epidemiology and clinical studies in primary and secondary prevention of stroke.
Use of novel neuroimaging techniques to better understand the mechanisms and prognosis of stroke and cerebral small vessel disease.
Role of the gut microbiota in vascular and brain health.
Use of digital health technologies to improve the management of stroke.
Dr G.K.K. Lau
Tel: 2255 4249
Chronic obstructive pulmonary disease (COPD) and bronchiectasis − mechanisms of neutrophil recruitment; role of transforming growth factor, TGF-beta; bronchial epithelial injury airways remodelling; biomarker and stem cell regeneration.
Lung cancer − molecular genetics; circulating tumour markers; environmental risk factor and genes interaction in pathogenesis; novel therapeutics in lung cancer; screening of lung cancer.
Obstructive sleep apnoea − cardiometabolic aspects of OSA; intermittent hypoxia exposure animal and cell culture models.
Professor M.S.M. Ip
Tel: 2255 4605
Rheumatology and Clinical Immunology:
Systemic lupus erythematosus (SLE) and other autoimmune diseases
Is SLE a single disease entity or a collection of autoimmune disorders?
Genetic and genomic studies of systemic lupus erythematosus.
Evaluation of the Lupus Low Disease Activity State as an outcome measure of systemic lupus erythematosus.
Treatment response measure in systemic lupus erythematosus.
Amyotrophic dermatomyositis and anti-MDA-5 antibody syndrome.
Professor C.S. Lau
Tel: 2255 3356
What are the molecular and cellular defects and the underlying mechanisms in immune cells that contribute to the development of lupus?
What are the potential roles of non-coding RNAs as immune regulators and biomarkers for SLE?
What is the role of AIM2 inflammasome in lupus?
How can we exploit the lupus-associated molecular defects as tools for predicting disease progression and treatment response in patients?
Molecular and cellular dysregulation in systemic lupus erythematosus.
Immunobiology of innate immune receptors.
Dr V.S.F. Chan
Tel: 2255 5995
Using diffusion weighted imaging as an imaging biomarker for axial spondyloarthritis.
Machine learning for magnetic resonance imaging in axial spondyloarthritis.
Biomarkers for spondyloarthritis.
Cardiovascular risks and comorbidities in spondyloarthritis.
Dr H.Y. Chung
Tel: 2255 4385
Immunology & Allergy
Drug allergy: epidemiology, clinical characteristics and diagnostics.
Anaphylaxis: epidemiology, management, specific syndromes and healthcare intervention.
Immunotherapy: Allergen immunotherapy and immunological changes with use of immune checkpoint inhibitors.
Primary and Secondary Immunodeficiences: Diagnostics and cost-effectiveness of subcutaneous immunoglobulin in Hong Kong.
Hereditary Angioedema: Genetics, clinical modifiers, therapeutics and Hong Kong HAE registry.
Dr P.H. Li
Tel: 2255 3348
Dr K.H. Chan
Tel: 2255 2368